

**COMMON DRUG REVIEW Agenda For Spring 2009**

<u>Drug</u>	<u>Relevant Information</u>	<u>Date for CEDAC Recommend. Release</u>
<b>Abatacept (Orencia) Bristol-Myers, Squibb</b>	Indication: Juv. Rheum. Arthritis New Submission	February 2009
<b>Alendronate Sodium cholecalciferol (Fosavance) Merck Frosst Ltd.</b>	Indication: Osteoporosis New Submission	February 2009
<b>Dabigatran etexilate Boeinger-Ingelheim</b>	Indication: Prevention of VTE New Submission	Late January 2009
<b>Darifenacin hydrobromide (Enablex) Novartis</b>	Indication: Overactive Bladder Resubmission #1	Late January 2009
<b>Infliximab (Remicade) Centocor Inc.</b>	Indication: Ulcerative Colitis New Submission	February 2009
<b>Insulin glulisine (Apidra) Sanofi-Aventis</b>	Indication: Diabetes Type 1 & 2 New Submission	Late January 2009
<b>Levodopa/Carbidopa (Duodopa) Solvay Pharma</b>	Indication: Parkinson's Disease New Submission	March 2009
<b>Methylnaltrexone bromide (Relistor) Wyeth Canada</b>	Indication: Opioid-induced constip. New Submission	February 2009
<b>Natalizumab (Tysabri) Biogen Idec Canada</b>	Indication: MS Relapsing/remit New Submission	February 2009
<b>Olmestartan medoxomil (Olmotec) Schering-Plough</b>	Indication: Hypertension New Submission	March 2009
<b>Olmestartan medoxomil + HCT (Olmotec Plus) Schering-Plough</b>	Indication: Hypertension w/ CHF New Submission	March 2009
<b>Sitaxsentan sodium (Thelin) Encysive Canada</b>	Indication: Pulm Artery HTN III Resubmission #1	Late January 2009
<b>Sodium oxybate (Xyrem) Valeant Canada</b>	Indication: Narcolepsy Resubmission #1	Late January 2009
<b>Solifenacin succinate (Vesicare) Astellas Pharma</b>	Indication: Overactive Bladder Resubmission #1	Late January 2009
<b>Tenofovir disoproxil fumarate (Viread) Gilead Sciences Ltd.</b>	Indication: Chronic Hep B New Submission	February 2009
<b>Teriparatide injectable rDNA (Fortio) Eli Lilly</b>	Indication: Glucocorticoid- induced osteoporosis New Submission	March 2009
<b>Ustekinumab (Stelara) Janssen-Ortho</b>	Indication: Psoriasis New Submission	April 2009

Note: All status reports available at [www.cadth.ca](http://www.cadth.ca) Click on "Common Drug Review", then  
"Recommendations & Status of Submissions"